Anti‐CCP Antibody, a Marker for the Early Detection of Rheumatoid Arthritis
- 19 November 2008
- journal article
- review article
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1143 (1), 268-285
- https://doi.org/10.1196/annals.1443.013
Abstract
Rheumatoid arthritis (RA) is a common autoimmune disease characterized by chronic inflammation of synovial joints. In most cases this will lead to the formation of pannus tissue, ultimately leading to joint destruction. Early diagnosis, coupled with aggressive use of disease-modifying antirheumatic drugs, has been shown to have a favorable effect on the course of the disease. Therefore, early and accurate diagnosis has become increasingly important. Several sets of criteria have been published to achieve such an early diagnosis, and all of them include measurement of antibodies directed to citrullinated peptides or proteins. This review summarizes our present knowledge about the most well-known and established test to measure these antibodies, the anti-CCP test, which measures antibodies directed to cyclic citrullinated peptides. We describe the current views on how these antibodies are generated and how genetic and environmental parameters are important in this process. The anti-CCP test is more specific than the commonly used RF test (95% versus less than 90%) and has a comparable sensitivity (more than 70%). These antibodies are detectable very early in the disease and are reported to predict the development of erosive RA. Increasing evidence supports a role for these antibodies in the pathology of the disease. In conclusion, testing for anti-CCP autoantibodies is widely accepted as an indispensable tool for diagnosis and early treatment in the management of rheumatoid arthritis patients.Keywords
This publication has 101 references indexed in Scilit:
- Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic miceThe Journal of Experimental Medicine, 2008
- Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2008
- Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker resultsAnnals Of The Rheumatic Diseases, 2007
- Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of responseAnnals Of The Rheumatic Diseases, 2007
- The performance of anti–cyclic citrullinated peptide antibodies in predicting the severity of radiologic damage in inflammatory polyarthritis: Results from the Norfolk Arthritis RegisterArthritis & Rheumatism, 2007
- Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trialArthritis & Rheumatism, 2007
- Contribution of anti-cyclic citrullinated peptide antibody and rheumatoid factor to the diagnosis of arthropathy in haemochromatosisAnnals Of The Rheumatic Diseases, 2007
- Diagnostic and predictive value of anti-cyclic citrullinated protein antibodies in rheumatoid arthritis: a systematic literature reviewAnnals Of The Rheumatic Diseases, 2005
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988
- The shared epitope hypothesis. an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritisArthritis & Rheumatism, 1987